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Dryad in the UK and USA - prospective and retrospective data publication 
Health-related research in the UK is estimated to cost around £8.5 billion per annum and the 
National Institute of Health invested $32.3 billion in the US (1, 2). This research, especially 
clinical trials, generates a huge amount of data, much of which carries importance far beyond 
the primary analysis. Although the trial team may publish secondary analyses, it is not 
uncommon for the study team to move on to the next project without fully exploiting the 
database. This costly and hard-won data may then sit on a computer for many years before 
finally being discarded. 
In recent years there has been a drive to publish clinical datasets, as well as reporting 
findings. It is most common to do this at the same time or shortly after the paper has been 
published. Dryad is a digital repository recommended by Toxicological Sciences which stores 
data from publications for free access.  At Toxicological Sciences, data sharing is voluntary 
and highly encouraged, and it is free for authors to do so as the costs are covered by the 
journal. 
Prospective data publishing refers to publishing datasets alongside the original paper with the 
primary analysis. Retrospective data publishing is when datasets are publishing after the 
research paper is published.  
Based on our recent experience of publishing a retrospective dataset (3, 4), this article aims to 
provide authors with a guide on how to prospectively or retrospectively publish their data.  
The data is citeable and freely accessible to all web users. 
 
Importance of data sharing 
Making the trial dataset publicly available allows other study teams to explore their own 
hypotheses, to conduct individual patient data meta-analysis, and obtain data in their 
preferred form. It also allows the primary analysis to be checked. According to the Wellcome 
Trust, transparency should be encouraged as it leads to higher quality research, better value 
for money and higher quality science. (5) This is important not only for unpublished trials, but 
also for those that are already published. 
Whilst the sharing of data has multiple benefits, there are also dangers of not sharing data. 
Incomplete analysis of data reduces the amount of information about the condition under 
study. Ultimately, this can compromise treatment choices leading to lower levels of health 
and patient care.
 (6)
 It can also allow errors in the analysis to go unrecognised leading to the 
publication of inaccurate results and conclusions. Most commonly this is accidental, but there 
have been repeated episodes where results have been fabricated, and the risk of this is also 
reduced with data publication. In the long run data sharing leads to a higher quality of 
research, with subsequent individual benefits through improved patient care.  
Some academics have concerns about releasing data, fearing that they will lose control of 
their project and data. It is feared that others may rush to conduct inappropriate secondary 
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analyses, or that those with vested commercial or academic interests may seek to misuse the 
data to reach contradictory conclusions. If there are these fears are justified then it is 
reasonable to state a time at which the data will be published (e.g. 6 months or 2 years after 
the study ends), thus allowing the primary research team to complete all their secondary 
analyses first.  
Anonymising data  
Before any data is submitted, measures must be taken to ensure the data is anonymised to an 
acceptable level. This is especially important with open access data repositories like Dryad 
where anyone can view the information.  
Hrynaszkiewicz et al, suggest minimum standards to ensure confidentiality with data 
sharing.(7) An important distinction is made between direct and indirect patient identifiers. 
Direct identifiers, such as name or date of birth, have a high probability of being able to 
identify an individual and so researchers should avoid publishing these if at all possible. In 
contrast, indirect indicators such as area of residence or hospital site have a low risk of 
accurately identifying an individual, even with multiple indirect variables. The authors 
recommend using less than 3 indirect identifiers when publishing data. More indirect (or any 
direct) identifiers may compromise anonymity and patient confidentiality.  If three or more 
indirect identifiers (or any direct identifiers) are used, explicit justification must be given and 
permission sought from an independent ethics committee. (7) 
There are multiple formats in which to store the data, but it is suggested that databases are 
stored using Microsoft Excel. (7) Although it is not as comprehensive as specialist databases 
such as SPSS, it is widely used and so makes the data more accessible. It also suggested data 
must be “cleaned”, removing errors, missing data and duplicate information. The data should 
also be “well annotated”, meaning that any coded headings or short abbreviations must be 
fully explained. This is particularly a problem with Excel where the headings are usually 
shortened (e.g. ‘OXYPRE’ might be used as an abbreviation for ‘oxytocin infusion used prior 
to birth for augmentation of labour’) and data within databases is commonly coded (e.g. 1 for 
‘yes’, 2 for ‘no’ and 999 for ‘missing data’). If this is the case the codes may need to be 
lengthened, or a supplementary page of descriptions and definitions may need to be added.  
Without the decoding, the data becomes difficult or impossible to interpret, and this can itself 
lead to errors in analysis and interpretation. 
(8)
 
Consent for data publication should be sought directly from the study participants if possible. 
If explicit consent has not been gained, then appropriate reasons must be given. This will be 
no problem for those studies that have planned to share the data from the start. For those 
seeking to share data retrospectively, however, obtaining informed consent from each patient 
is very unlikely to be achievable. In this case it is suggested that permission be sought from 
the local Caldicott Guardian, as well as the ethics committee who originally approved the 
study. They would usually be happy for this so long as the appropriate measures have been 
taken to anonymise the data. 
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For those publishing data retrospectively, consent for publication also needs to be sought 
from all authors of the original publication, as the data needs to be released under a Creative 
Commons 0 license (CC0). A CC0 license is a ‘no rights reserved’ licence and waives the 
restriction of copyright law. This means the data may be used freely and without restriction 
for future user, so that they may enhance and build upon the data. (9) 
Data submission 
Whether data is being submitted retrospectively or prospectively, the submission procedure is 
the same. Dryad accepts data in all forms so that any research team can submit datasets to the 
repository.  Each dataset is given a Direct Object Identifiers (DOI), which can be used to cite 
the dataset and to access it. This gives authors credit for use of their datasets.  
If submission is prospective the dataset can be referenced within the published paper, with 
the DOI number. Dryad offers a the option of keeping the data private during peer review and 
then making it public once the paper with the primary analysis has been published. 
If the dataset is published retrospectively, the process remains the same - the only difference 
being that the DOI cannot be easily added or linked to the original publication. There are 
ways around this. For our retrospective data publication, the link was made in a BMJ letter, 
(4)
 
whilst for those journals with online response systems (such as the BMJ), the DOI can be 
submitted as a rapid response to the article. This can help future users to access the dataset.  
Dryad states on their website that the submission procedure usually takes less than 15 
minutes. Therefore it is a relatively easy process once the dataset has been prepared. 
The Future 
In this article so far we have only discussed the possibility of publishing clinical trial data, 
however even the most basic scientific experiments produce data. With online repositories 
such as Dryad, it is now possible to have all raw datasets published relatively easily. Dryad 
guarantees data for 10 years to be accessible with no extra cost to the author.  
This would mean datasets from large scale trials to basic scientific papers will be available to 
access. The raw data can be compiled and even used to create new analyses without having to 
necessarily preform any experiments. With the help of Dryad, authors of the original dataset 
can be credited for their contributions. Therefore this can be of benefit to the research 
community as a whole. 
The field of toxicology is always looking to improve the quality of scientific research. At 
Toxicological Sciences it is not only the accuracy of results which is emphasised, it also the 
reproducibility of the results. 
(10)  
Research in toxicology is not primarily focussed on new 
treatments but rather preventing harmful effects. This is of particular significance, as 
hypothetically data can be analysed from multiple sources on the same treatment and 
correlation of side effects or potential risk factors can be extrapolated.  
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At Toxicological sciences it is encourage to share data not to treat it as a protected possession 
but rather something openly shared, and with the correct systems in place this is possible.
(11)
 
Conclusion 
Data publication is becoming an increasingly important part of research dissemination - 
indeed some major funders now require it as a condition of their funding. The process is 
simple and we would encourage those with datasets from previous pieces of research to 
increase its value by sharing their data in the way in which we have outlined. 
 
Fig 1 – how to submit data to Dryad
(12)
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